Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 6/20 | 0.75 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.58 |
| ▸ | NPY1R | P25929 | 2/20 | 0.58 |
| ▸ | NPY4R | P50391 | 2/20 | 0.58 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.58 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.58 |
| ▸ | VIPR2 | P41587 | 2/20 | 0.57 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.57 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.57 |
| ▸ | HRAS | P01112 | 1/20 | 0.57 |
| ▸ | KRAS | P01116 | 1/20 | 0.57 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30601869 | 0.89 | TFPI (0.79) | TFPIVIPR2VIPR1 | |
| SCHEMBL30436216 | 0.88 | TFPI (0.79) | TFPIVIPR2VIPR1 | |
| SCHEMBL29409522 | 0.88 | TFPI (0.73) | TFPIIL23RKEAP1VIPR2VIPR1 | |
| SCHEMBL29960067 | 0.88 | NPY4R (0.62) | TFPINPY5RNPY1RNPY4R | |
| SCHEMBL29903297 | 0.87 | TFPI (0.71) | TFPIVIPR2VIPR1 | |
| SCHEMBL31419699 | 0.87 | TFPI (0.71) | TFPIVIPR2VIPR1 | |
| SCHEMBL29519384 | 0.87 | TFPI (0.68) | TFPINPY5RNPY1RNPY4RVIPR2 | |
| SCHEMBL30432039 | 0.86 | TFPI (0.67) | TFPIVIPR1 | |
| SCHEMBL29430569 | 0.86 | TFPI (0.70) | TFPINPY5RNPY1RNPY4RIL23R | |
| SCHEMBL31683364 | 0.86 | TFPI (0.67) | TFPIKEAP1VIPR2VIPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240392271-A1 | ENGINEERED CASX REPRESSOR SYSTEMS | SCRIBE THERAPEUTICS INC. | 2024-11-28 | — | — | US | claimed |
| CN-118556124-A | Engineered CASX repressor systems | 斯克里贝治疗公司 | 2024-08-27 | — | — | CN | claimed |
| EP-4405479-A2 | ENGINEERED CASX REPRESSOR SYSTEMS | Scribe Therapeutics Inc. (US) | 2024-07-31 | — | — | EP | claimed |
| EP-4351660-A2 | PARTICLE DELIVERY SYSTEMS | Scribe Therapeutics Inc. (US) | 2024-04-17 | — | — | EP | claimed |
| US-20240100185-A1 | COMPOSITIONS AND METHODS FOR THE TARGETING OF PTBP1 | SCRIBE THERAPEUTICS INC. | 2024-03-28 | — | — | US | claimed |
| US-20240026386-A1 | COMPOSITIONS AND METHODS FOR THE TARGETING OF BCL11A | SCRIBE THERAPEUTICS INC. | 2024-01-25 | — | — | US | claimed |
| US-20240026385-A1 | ENGINEERED CLASS 2 TYPE V CRISPR SYSTEMS | SCRIBE THERAPEUTICS INC. | 2024-01-25 | — | — | US | claimed |
| EP-4255502-A2 | COMPOSITIONS AND METHODS FOR THE TARGETING OF BCL11A | Scribe Therapeutics Inc. (US) | 2023-10-11 | — | — | EP | claimed |
| EP-4256054-A1 | ENGINEERED CLASS 2 TYPE V CRISPR SYSTEMS | Scribe Therapeutics Inc. (US) | 2023-10-11 | — | — | EP | claimed |
| CN-116801913-A | Compositions and methods for targeting BCL11A | 斯克里贝治疗公司 | 2023-09-22 | — | — | CN | claimed |
| WO-2023049742-A2 | ENGINEERED CASX REPRESSOR SYSTEMS | SCRIBE THERAPEUTICS INC. (US) | 2023-03-30 | — | — | WO | claimed |
| EP-4121535-A1 | COMPOSITIONS AND METHODS FOR THE TARGETING OF C9ORF72 | Scribe Therapeutics Inc. (US) | 2023-01-25 | — | — | EP | claimed |
| WO-2022261150-A2 | PARTICLE DELIVERY SYSTEMS | SCRIBE THERAPEUTICS INC. (US) | 2022-12-15 | — | — | WO | claimed |
| EP-4069716-A1 | PARTICLE DELIVERY SYSTEMS | Scribe Therapeutics Inc. (US) | 2022-10-12 | — | — | EP | claimed |
| CN-115175921-A | Particle delivery system | 斯克里贝治疗公司 | 2022-10-11 | — | — | CN | claimed |
| WO-2022120089-A1 | COMPOSITIONS AND METHODS FOR THE TARGETING OF PTBP1 | SCRIBE THERAPEUTICS INC. (US) | 2022-06-09 | — | — | WO | claimed |
| WO-2022120094-A2 | COMPOSITIONS AND METHODS FOR THE TARGETING OF BCL11A | SCRIBE THERAPEUTICS INC. (US) | 2022-06-09 | — | — | WO | claimed |
| WO-2022120095-A1 | ENGINEERED CLASS 2 TYPE V CRISPR SYSTEMS | SCRIBE THERAPEUTICS INC. (US) | 2022-06-09 | — | — | WO | claimed |
| CN-122029277-A | Engineered class 2V-type CRISPR system | 斯克里贝治疗公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20220089707-A1 | MONOCLONAL ANTIBODIES AGAINST MHC-BOUND HUMAN DICKKOPF-1 PEPTIDES AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-03-24 | — | — | US | disclosed |